Julia O. Davidova

BCR/ABL, IKZF deletions and FLT3-ITD as the targets for relapsed/refractory B-cell acute lymphoblastic leukemia treatment: Blinatumomab combined with Tyrosine kinase inhibitors and ATRA

E. Parovichnikova, O. Gavrilina, S. Bondarenko, 2020 .

Protein Kinase D Promotes in Vitro Osteoclast Differentiation and Fusion*

Masato Yamamoto, R. Gopalakrishnan, E. Jensen, 2013, The Journal of Biological Chemistry.

Blinatumomab + Tyrosine Kinase Inhibitors in the Treatment of Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Patients - Clinical Efficacy and Peripheral Blood Lymphocytes Subpopulations Kinetics

E. Parovichnikova, I. Galtseva, A. Sokolov, 2016 .